The charts of Teva Pharmaceutical Industries, Inc. have been in a five-year decline but it looks like aggressive buying is making a return to this name. In the daily bar chart of TEVA, below, we can see that buyers have shown up in the $7-$6 area in August, September and October and again this March. The On-Balance-Volume (OBV) line has been rising for much of the past 12 months and suggests we are seeing some significant accumulation.

Ladies and gentlemen, thank you for standing by, and welcome to today's Teva Pharmaceutical First Quarter 2020 Financial Results. Delay, I would now like to hand the conference over to presenter today, Kevin Mannix, Senior Vice President and Head of Investor Relations. Thank you, operator, and thank you, everyone, for joining us today to discuss Teva's First Quarter 2020 Financial Results.

The U.S. death toll from the coronavirus that causes COVID-19 rose above 87,000 on Saturday, as new outbreaks were reported from states where stay-at-home orders are set to expire and in states that never imposed them, raising concerns that the reopening of economies will spur new infections.

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Teva Pharmaceutical cleared that benchmark Thursday, with a jump from 80 to 90 Thursday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are up 11% at 1:50 p.m. EDT after the drugmaker announced first-quarter earnings that beat expectations. For most drugmakers, 5% growth would be a slow quarter, but Teva has been struggling of late, with its multiple sclerosis drug Copaxone facing generic competition and a decline in its U.S. generic business, which resulted in revenue falling 8% year over year -- 5% in local currency terms -- in 2019. On the non-COVID-19 plus side, U.S. sales of Austedo, which treats tardive dyskinesia and Huntington's disease chorea, were up 64% year over year to $122 million.

Beginning in late February, we witnessed the broad-based S&P 500 endure the fastest descent into bear market territory in history -- it took a little over three weeks. Every bear market correction in history has proved to be an excellent buying opportunity for long-term-minded investors. This means that if you buy businesses with game-changing potential at a discount during a bear market, you'll be setting yourself up to make a lot of money.

Generic drugmaker Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported a first-quarter earnings beat as the company managed to maintain business continuity, CEO Kare Schultz said on CNBC's "Squawk on the Street."Teva's 'Very Good' Quarter Teva is dedicated to supplying therapies to the 200 million people who use its generic drugs and this resulted in a "very good" quarter, the CEO said.Looking forward, the company expects to see "some reversal" of the strong demand seen in March, but Schultz said full-year revenue should fall within its guidance.Teva Supply Chain Update One of Teva's drugs, propofol, experienced shipping delays due to the COVID-19 pandemic. Part of the problem stems from a reduction in air traffic, less air cargo availability and some countries placing new restrictions on imported goods.While air cargo issues remain a problem, Teva is seeing improving conditions, as it has been able to increase volume outputs, but with higher transportation costs.In the meantime, all of Teva's facilities are operating at "full capacity," Schultz said, and the "majority" of logistical problems have been overcome.Teva And The Hydroxychloroquine Controversy Teva is one of the few makers of the anti-malaria drug hydroxychloroquine, which has come under its fair share of controversy.The CEO said he can't at this time offer a "clarifying answer" on the efficacy of the drug in treating COVID-19. The ultimate responsibility rests with the health care professionals, he said.View more earnings on TEVANevertheless, Teva was able to respond to the growing demand for the drug and was "quite successful" in shipping the product, Schultz said. Teva CEO On Coronavirus Second Wave Concerns The coronavirus could return for a "second wave" in the fall season, but it is "too early to say" what, if any, actions hospitals are taking now to prepare themselves, Schultz said.It is nevertheless important for all companies to increase the production of products to better prepare in the event of a second wave outbreak, he said. Teva shares were up 10.11% at $11.54 at the time of publication Thursday.Related Links:Chloroquine, Hydroxychloroquine And Coronavirus: What You Should KnowSanofi CEO Talks Coronavirus Vaccine Development, Potential TreatmentSee more from Benzinga * Papa John's CEO Says Chain Had Best Month Ever Due To More Than Just Coronavirus Trends * Coronavirus Drives Surge In Online Grocery Penetration For Players Like Amazon Prime Now, Walmart * These Analysts Aren't Supporting Beyond Meat's Stock Surge(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) ("Teva"), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as previously announced.

The National Institute of Allergy and Infectious Diseases (NIAID) said it launched a clinical trial testing hydroxychloroquine and azithromycin in 2,000 patients with mild and moderate cases of COVID-19. Hydroxychloroquine is approved by the Food and Drug Administration (FDA) to treat malaria, lupus, and rheumatoid arthritis; azithromycin is a commonly prescribed antibiotic. The trial was announced during Dr. Rick Bright's testimony before a House of Representatives committee on Thursday. Bright has filed a whistleblower lawsuit alleging that his reluctance to promote hydroxychloroquine as a treatment for COVID-19 led to his demotion within the National Institutes of Health. Teva Pharmaceutical Industries Ltd. donated the hydroxychloroquine for the trial, which is evaluating whether the drug combination can prevent hospitalization and death. "Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes," NIAID director Dr. Anthony Fauci said in a statement. The FDA in March granted an emergency use authorization to hydroxychloroquine and chloroquine as COVID-19 treatments. More recently, the regulator authorized Gilead Sciences Inc.'s remdesivir as a COVID-19 treatment; however, there are no proven, FDA-approved therapies that treat the disease caused by the novel coronavirus. There are dozens of other clinical trials underway evaluating hydroxychloroquine in COVID-19 patients.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY® (fremanezumab) and the burden of migraine in Europe will be presented at the 6th Congress of the European Academy of Neurology (EAN), being held virtually from 23-26 May 2020. Additionally, Teva will present data on the long-term safety and efficacy of COPAXONE® (glatiramer acetate injection). This year’s EAN congress is a virtual meeting due to the global coronavirus pandemic. All Teva abstracts will be published in a supplement to the European Journal of Neurology.

Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.

No matter how dire things may have appeared in previous bear markets, bull-market rallies eventually erase all evidence of downward moves in the stock market. Also keep in mind that you don't have to be rich to generate a handsome return from the stock market. With the exception of the oil and gas industry, there's probably not a harder-hit industry lately than bank stocks.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the China National Medical Products Administration (NMPA) has approved AUSTEDO® (Deutetrabenazine Tablets) for the treatment of chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults, after a priority review. China is the second country in the world after the U.S. to have approved AUSTEDO.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Shares of JetBlue Airways and Teva Pharmaceuticals jump strong on earnings Continue reading...

Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic.

Veteran value managers gathered by Ariel Investments earlier this week for a virtual discussion said they have been snapping up a wide-range of stocks during the coronavirus-induced volatility.

Teva Pharmaceutical beat Wall Street's first-quarter expectations Thursday, leading Teva stock to rocket to a three-month high. Teva also reaffirmed its revenue guidance for the year.